From November 15th to 16th, "The First China Pharmaceutical Valley · Future Biological Innovative Drug Conference" was held in Beijing. The conference focused on the hot topics of "biological innovation technology", "CXO and innovative drugs to the sea", "biomedical innovation, investment and financing" and other industry topics. It provides more cutting-edge perspectives and innovative ideas for the development of the whole industrial chain of the pharmaceutical industry. Academates, industry experts and representatives of many outstanding pharmaceutical enterprises gathered in Beijing Daxing to discuss the frontier trend, innovation trend, technological breakthrough and future development of the pharmaceutical industry, which brought new vitality and inspiration into the industry.
Gong Weimi, member of the Leading Party Group and deputy director of the Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee, said in his speech, Science leads development and innovation changes the world. Beijing has always attached great importance to the development of the medical and health industry, and is carrying out special policies and measures from the aspects of capital, talent and space to continuously promote the growth of the medical and health industry. At the same time, Daxing District has been at the forefront of Beijing in terms of medical and health park construction and industrial ecological policies, providing various services for the medical and health industry ecology. "Through the joint efforts of all parties and a combination of measures, the medical and health industry will certainly restore confidence and reshape the favorable development pattern." Gong Weimi said.
Daxing hosts the capital's science and technology, and many outstanding entrepreneurs are taking Daxing as the development site for their careers and promoting the construction of the capital's science and technology innovation center. Whether from domestic or foreign innovation, Daxing has the potential to attract global attention and become the core force in the future development of China's biomedical industry.
Jiang Jiandong, academician of the Chinese Academy of Engineering and president of the Institute of Materia Medica of the Chinese Academy of Medical Sciences, delivered a report on "Star-Shining China's Original New Drugs". Academician Jiang Jiandong said that the development of innovative drugs in China did not happen overnight, but went through the process of imitation, learning from western, and then independent innovation. He used the "head goose effect" to show the importance of key targets, and said that in drug research and development, we should pursue scientific truth, integrate the wisdom of Chinese philosophy, and add more "stars" to the development of innovative drugs in China.
Professor Du Jie from Beijing Institute of Cardiovascular and Pulmonary Vascular Diseases, Capital Medical University, introduced the research progress of Sungen Biomedical SGC001, which has the potential to become the world's first antibody drug for myocardial infarction. Sungen Biomedical is an innovation-driven biomedical technology company focused on the discovery, development and commercialization of original antibody drugs and ADCs. Sungen Biomedical's SGC001 injection is a Class 1 therapeutic biological product and is mainly used for the treatment of myocardial infarction (AMI). According to Professor Du, SGC001 can specifically bind target antigen, block antigen binding to its receptor, reduce local inflammatory response, promote local blood perfusion, and thus play a therapeutic role in reducing myocardial infarction mortality and improving cardiac function.
Professor Liu Yuling, Institute of Materia Medica, Chinese Academy of Medical Sciences & Chinese Union Medical College, shared the innovation and breakthrough of original new drugs in China, by taking the world's first natural hypoglycemic drug "total alkaloids from mulberry branches" as a sample, which contains effective components from plant sources. She said that the innovative discovery of "total alkaloids from mulberry branches" broke the perception that traditional Chinese medicine alone cannot effectively reduce blood sugar, and opened up a new chapter in diabetes treatment. Based on the multiple pharmacological effects of "Mulberry branch total alkaloids", from lowering glucose, improving metabolism, to treating polycystic ovary syndrome, weight loss, non-alcoholic fatty liver disease and other new indications, it is expected to fill the international gap and become a big variety.
At the meeting, the Bioeconomy Committee of the China Asian Economic Development Association and the China Pharmaceutical Valley Biomedical Industry Alliance were officially established. This marks an important step in the field of bioeconomy in our country. It will help to attract experts, scholars and entrepreneurs related to bioeconomy across the country, provide more strength for the development of bioeconomy, and promote further cooperation and innovation in the field of medicine.
Source: People's Daily Online
(Editors: Chi Mengrui, Gao Xing)
Updated: Dec 17, 2024
